170 related articles for article (PubMed ID: 37762037)
1.
Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
[No Abstract] [Full Text] [Related]
2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
3. LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple-negative breast cancer.
Wang W; He X; Wang Y; Liu H; Zhang F; Wu Z; Mo S; Chen D
Cancer Sci; 2022 Aug; 113(8):2484-2495. PubMed ID: 35411612
[TBL] [Abstract][Full Text] [Related]
4. High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer.
Qin Z; Wang Y; Tang J; Zhang L; Li R; Xue J; Han P; Wang W; Qin C; Xing Q; Yang J; Zhang W
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054424
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Mutant p53 in the Non-Coding RNA World.
Di Agostino S
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204575
[TBL] [Abstract][Full Text] [Related]
7. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
8. Non-coding RNAs, guardians of the p53 galaxy.
Chen S; Thorne RF; Zhang XD; Wu M; Liu L
Semin Cancer Biol; 2021 Oct; 75():72-83. PubMed ID: 32927018
[TBL] [Abstract][Full Text] [Related]
9. LINC01605 regulates proliferation, migration and invasion of colorectal cancer cells via targeting miR-3960/SOX11.
Hu SS; Fu L; Han SY; Li XL; Zhang LD
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1322-1329. PubMed ID: 33629302
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex.
Verduci L; Ferraiuolo M; Sacconi A; Ganci F; Vitale J; Colombo T; Paci P; Strano S; Macino G; Rajewsky N; Blandino G
Genome Biol; 2017 Dec; 18(1):237. PubMed ID: 29262850
[TBL] [Abstract][Full Text] [Related]
11. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
12. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
13. Mutant TP53 posttranslational modifications: challenges and opportunities.
Nguyen TA; Menendez D; Resnick MA; Anderson CW
Hum Mutat; 2014 Jun; 35(6):738-55. PubMed ID: 24395704
[TBL] [Abstract][Full Text] [Related]
14. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
15. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
[TBL] [Abstract][Full Text] [Related]
16. Histone modifications affect differential regulation of TGFβ- induced NADPH oxidase 4 (NOX4) by wild-type and mutant p53.
Boudreau HE; Ma WF; Korzeniowska A; Park JJ; Bhagwat MA; Leto TL
Oncotarget; 2017 Jul; 8(27):44379-44397. PubMed ID: 28574838
[TBL] [Abstract][Full Text] [Related]
17. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
18. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
19. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 mediates survival of breast cancer cells.
Lim LY; Vidnovic N; Ellisen LW; Leong CO
Br J Cancer; 2009 Nov; 101(9):1606-12. PubMed ID: 19773755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
